Skip to main content
Log in

Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

A 73-year-old female with hepatocellular carcinoma (HCC) received percutaneous transhepatic portal vein embolization (PTPE) before extensive right lobe hepatectomy. Serum levels of des-gamma-carboxy-prothrombin (DCP) were increased and remained at a high level until hepatectomy. Immunohistochemical examination revealed that an increased expression of DCP was demonstrated not only in HCC tissues, but also in the non-cancerous liver of the right lobe, where portal blood flow was blocked off as a result of PTPE. The serum level of DCP is known to be greatly increased in patients with HCC accompanied by portal vein invasion. We speculate that this increased DCP level is caused by both increased DCP production in HCC tissue and the surrounding non-cancerous liver, where portal flow is blocked off as a result of portal invasion by HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zhu R, Yang J, Xu L, et al. Diagnostic performance of des-gamma-carboxy prothrombin for hepatocellular carcinoma: a meta-analysis. Gastroenterol Res Pract. 2014;2014:529314.

    PubMed Central  PubMed  Google Scholar 

  2. Gao P, Li M, Tian QB, Liu DW. Diagnostic performance of des-gamma-carboxy prothrombin (DCP) for hepatocellular carcinoma: a bivariate meta-analysis. Neoplasma. 2012;59:150–9.

    Article  CAS  PubMed  Google Scholar 

  3. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Lamerz R, Runge M, Stieber P, Meissner E. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res. 1999;19:2489–93.

    CAS  PubMed  Google Scholar 

  5. Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.

    Article  CAS  PubMed  Google Scholar 

  6. Nakao A, Suzuki Y, Isshiki K, et al. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol. 1991;86:62–6.

    CAS  PubMed  Google Scholar 

  7. Kato A, Yasuda H, Togawa A, et al. Measurement of des-gamma-carboxy prothrombin levels in hemodialysis patients positive for anti-hepatitis virus C antibody. Clin Nephrol. 2002;58:296–300.

    Article  CAS  PubMed  Google Scholar 

  8. Tamano M, Sugaya H, Oguma M, et al. Immunolocalisation of PIVKA-II in paraffin-embedded specimens of hepatocellular carcinoma. Liver. 1999;19:406–10.

    Article  CAS  PubMed  Google Scholar 

  9. Murata K, Suzuki H, Okano H, et al. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36:161–70.

    CAS  PubMed  Google Scholar 

  10. Yuan LW, Tang W, Kokudo N, et al. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma. Oncol Rep. 2004;12:269–73.

    CAS  PubMed  Google Scholar 

  11. Xiang CH, Zhang W, Inagaki Y, et al. Measurement of serum and tissue des-gamma-carboxyprothrombin in resectable hepatocellular carcinoma. Anticancer Res. 2008;28:2219–24.

    CAS  PubMed  Google Scholar 

  12. Tang W, Kokudo N, Sugawara Y, et al. Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep. 2005;13:25–30.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tetsuro Sohda.

Ethics declarations

Conflict of Interest:

Tetsuro Sohda, Kaoru Iwata, Akira Anan, Hideo Kunimoto, Kaoru Yotsumoto, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Akinobu Osame, Shinichi Kora, Jun Ohishi, Yasushi Yamauchi, Tomoaki Noritomi, Kengo Yoshimitsu, Yuichi Yamashita, and Shotaro Sakisaka declare that they have no conflict of interest.

Human/Animal Rights:

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).

Informed Consent:

Informed consent was obtained from all patients for being included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sohda, T., Iwata, K., Anan, A. et al. Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma. Clin J Gastroenterol 8, 330–334 (2015). https://doi.org/10.1007/s12328-015-0603-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-015-0603-x

Keywords

Navigation